RCKT

RCKT

Rocket Pharmaceuticals Inc. Common Stock

$3.070+0.000 (0.000%)

实时价格

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$3.070

最高价

$3.070

最低价

$3.070

成交量

3.11M

公司基本面

交易统计

相关新闻

Analyst Upgrades

Canaccord Genuity Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $11

Canaccord Genuity analyst Whitney Ijem maintains Rocket Pharmaceuticals with a Buy and lowers the price target from $34 to $11.

查看更多
Canaccord Genuity Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $11
Analyst Upgrades

Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty

Rocket Pharmaceuticals faces trial delays, multiple downgrades, and reduced success expectations following RP-A501 safety concerns.

查看更多
Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty
Analyst Upgrades

Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty

Rocket Pharmaceuticals faces trial delays, multiple downgrades, and reduced success expectations following RP-A501 safety concerns.

查看更多
Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty
Analyst Upgrades

B of A Securities Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $9

B of A Securities analyst Greg Harrison maintains Rocket Pharmaceuticals with a Buy and lowers the price target from $32 to $9.

查看更多
B of A Securities Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $9
Analyst Upgrades

BMO Capital Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $8

BMO Capital analyst Kostas Biliouris maintains Rocket Pharmaceuticals with a Outperform and lowers the price target from $30 to $8.

查看更多
BMO Capital Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $8
Analyst Upgrades

Scotiabank Maintains Sector Outperform on Rocket Pharmaceuticals, Lowers Price Target to $19

Scotiabank analyst Greg Harrison maintains Rocket Pharmaceuticals with a Sector Outperform and lowers the price target from $51 to $19.

Analyst Upgrades

Leerink Partners Downgrades Rocket Pharmaceuticals to Market Perform, Lowers Price Target to $8

Leerink Partners analyst Mani Foroohar downgrades Rocket Pharmaceuticals from Outperform to Market Perform and lowers the price target from $37 to $8.